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Abstract
There is a growing appreciation of the importance of gut microbiota to health and disease. This has been driven by advances 
in sequencing technology and recent findings demonstrating the important role of microbiota in common health disorders 
such as obesity. Moreover, the potential role of gut microbiota in influencing brain function, behavior, and mental health has 
attracted the attention of neuroscientists and psychiatrists. At the 29th International College of Neuropsychopharmacology 
(CINP) World Congress held in Vancouver, Canada, in June 2014, a group of experts presented the symposium, “Gut microbiota 
and brain function: Relevance to psychiatric disorders” to review the latest findings in how gut microbiota may play a role 
in brain function, behavior, and disease. The symposium covered a broad range of topics, including gut microbiota and 
neuroendocrine function, the influence of gut microbiota on behavior, probiotics as regulators of brain and behavior, and 
imaging the gut-brain axis in humans. This report provides an overview of these presentations.
Keywords: Behavior, brain imaging, immune, neuroendocrine, MRI, probiotic
Microbiota and Behavior
The role of the microbiome in the determination of behavior and 
cognition is increasingly being recognized (Cryan and Dinan, 
2012; Collins et al., 2013; Foster and McVey Neufeld, 2013; Lyte, 
2013). In fact, the development of the brain itself in the grow-
ing infant has been shown to be influenced by the microbiome 
(Douglas-Escobar et  al., 2013). As such, the communication of 
gut microbiota with the brain, through what is referred to as the 
microbiota-gut-brain axis, represents a new biological axis by 
which novel diet-based therapies can be designed to influence 
brain function and behavior. Early studies in animals first dem-
onstrated that the introduction of a single, unique bacterium in 
the gut resulted in the development of anxiety-like behavior in 
mice, with concomitant activation of neuronal regions in the 
brain that were dependent on information received from the gut 
via the vagus nerve (Goehler et al., 2005). Later studies showed 
that the transplantation of the fecal microbiome from one 
mouse strain displaying a phenotypic set of behaviors to another 
strain resulted in the recipient strain exhibiting the behavioral 
phenotype of the donor (Bercik et al., 2011a; Collins et al., 2013). 
Ongoing research continues to demonstrate in humans that the 
composition of the microbiota has a dramatic influence on the 
behavior of the individual. For example, the composition of the 
mucosal microbiota of cirrhotic patients was linked to poor cog-
nition (Bajaj et al., 2012).
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Much of our understanding related to how microbiota may 
influence behavior comes from animal studies that manipulate 
the composition and diversity of gut microbiota. The germ-free 
(GF) mouse has been a useful animal model to help determine 
the domains of behavior that are influenced by microbiota. The 
GF mouse model was established in 1957, where GF mice are 
raised in sterile/gnotobiotic environments and have no commen-
sal bacteria (Gustafsson et al., 1957; Gustafsson, 1959). Both the 
mucosal and the systemic immune systems of GF mice are imma-
ture, with reduced numbers of B lymphocytes and T lymphoctyes 
(Macpherson and Harris, 2004). A landmark study showed that GF 
mice have exaggerated stress-reactivity in response to restraint 
stress, revealed by increased plasma corticosterone and plasma 
adrenocorticotrophic hormone levels compared to specific patho-
gen-free (SPF) mice (Sudo et al., 2004). This publication was really 
the stimulus for neuroscientists to consider the GF mouse model 
(Sudo et al., 2004). The question arose as to whether or not GF mice 
would show an altered behavioral phenotype. Several research 
groups have examined behavior in germ-free mice; these studies 
are summarized in Table 1. Across these studies, some common 
findings have emerged. First of all, GF mice show reduced anxiety-
like behavior, compared to conventionally-housed mice, in the 
elevated plus maze (EPM) and light/dark test (Heijtz et al., 2011; 
Neufeld et al., 2011b; Clarke et al., 2013). Second of all, reconstitu-
tion of GF mice with strain-matched microbiota early in life is able 
to normalize many of the behaviors (Heijtz et al., 2011; Clarke et al., 
2013), whereas reconstitution of GF mice in adulthood was not 
able to change the reduced trait anxiety–like phenotype observed 
in the EPM (Neufeld et al., 2011a). Interestingly, one can argue that 
the behavioral phenotype is linked directly to the microbiota, as 
the transfer of SPF Balb/C microbiota to GF Swiss Webster (SW) 
mice reduced exploratory behavior compared to normal SW mice, 
while transfer of SPF SW microbiota to GF Balb/C mice increased 
exploratory behavior compared to normal Balb/C mice (Bercik 
et al., 2011a). In stress-sensitive F344 rats, GF rats showed reduced 
social interaction, reduced center entries in the open field (OF), 
and increased time spent in the corners of the OF (Crumeyrolle-
Arias et  al., 2014). These observations are opposite the explora-
tory and anxiety-like differences mentioned above in several 
non–stress sensitive strains of mice; however, these observations 
parallel social behavior deficits that have been reported in GF SW 
mice (Desbonnet et al., 2013). Together, the above studies identify 
both exploratory and anxiety-like behaviors and social behavior 
as domains that are influenced by microbiota. The suggestion 
that strains modulate the influence of microbiota is important to 
consider and was addressed in a recent paper using stress-sen-
sitive Balb/C mice. Researchers compared GF Balb/C mice to the 
offspring of conventionalized GF Balb/C mice (EX-GF) and showed 
less anxiety-like behavior in EX-GF mice in both the OF and in the 
marble burying test (Nishino et al., 2013). Monoassociation with 
Clostridium coccoides also reduced anxiety-like behavior, whereas 
monoassociation with Bifido infantis showed reduced activity in 
the OF and no changes in anxiety-like behavior compared to GF 
mice (Nishino et al., 2013). Understanding which microbiota spe-
cifically influence behavior is a central theme of ongoing research 
in this area.
Probiotic Studies in Animals
Several groups have examined the effect of probiotic adminis-
tration on behavior. Initial reports in rats showed no effect of 
probiotic administration to healthy rats. First, administration of 
Lactobacillus salivarius, B. infantis, or B. breve to healthy Sprague-
Dawley or Wistar rats had no effect on open field behavior 
(McKernan et  al., 2010). Second, administration of B.  infantis 
to healthy Sprague-Dawley rats showed no effect on depres-
sive-like behavior in the forced swim test (FST; Desbonnet 
et al., 2008): however, 45 days of treatment with B.  infantis in 
rats exposed to early-life maternal separation normalized 
stress-induced depressive-like behavior in the FST (Desbonnet 
et al., 2010). Similarly, probiotic treatment has been shown to 
be beneficial in animal models of infection and colitis (Bercik 
et al., 2010, 2011b). Specifically, administration of L. rhamnosous 
for 10  days normalized anxiety-like behavior induced by the 
parasite Trichuris muris (Bercik et  al., 2011b) and administra-
tion of B.  longum for 14  days normalized anxiety-like behav-
ior induced by dextran sodium sulphate colitis (Bercik et  al., 
2011b). Interestingly, a few studies have reported a change in 
behavior when probiotics are administered to healthy rodents. 
For example, 28-day administration of L.rhamnosous to Balb/C 
mice resulted in reduced anxiety-like behavior in the EPM 
and reduced depressive-like behavior in the FST (Bravo et al., 
2011). It has also been shown that B. Breve and B. Longum both 
significantly reduced anxiety-related behaviors, albeit with 
different profiles (Savignac et al., 2014), and the latter strain, 
but not former, enhanced cognitive function in healthy Balb/C 
mice (Savignac et al., 2015). Also, 14-day administration of the 
combination of L.  helveticus and B.  longum reduced anxiety-
like behavior in the defensive marble burying test in Wistar 
rats (Messaoudi et  al., 2011a). Interestingly, administration 
of this combination of probiotics to healthy human subjects 
showed a beneficial effect on anxiety and depression meas-
ures (Messaoudi et  al., 2011b). Other combinations of probi-
otics have been shown to reduce a sad mood triggered by a 
psychological stimulus (Steenbergen et al., 2015) and to reduce 
depression anxiety and stress scales whilst modulating the 
hypothalamic pituitary adrenal (HPA) axis in petrochemical 
workers (Mohammadi et al., 2015).
Microbiota, Immune Signaling, and 
the Brain
While several gut-brain pathways are suggested to play a role 
in microbiota-to-brain signaling (Cryan and Dinan, 2012; Foster 
and McVey Neufeld, 2013), this CINP symposium presented 
key findings related to the role of immune signaling in behav-
ior. Researchers in psychiatry and behavioral neuroscience 
are increasingly recognizing the importance of the adaptive 
immune system in behavior. Recombinase-activating gene-1 
(RAG-1) is a component of the adaptive immune recombination 
system (Chun et al., 1991). Deletion of RAG-1 results in the abil-
ity of lymphocytes to execute VDJ recombination, a mechanism 
of genetic recombination that rearranges variable (V), joining (J), 
and diversity (D) gene segments to create diversity in the varia-
ble chain of the T cell receptor. This deletion generates mice that 
lack mature T and B cells, thus silencing the adaptive immune 
system (Mombaerts et al., 1992). RAG1-/- mice (Cushman et al., 
2003) show reduced anxiety-like behavior. Mice lacking both β-2 
microglobulin and transporters associated with the antigen pro-
cessing genes (β2M−/−TAP−/−), resulting in the loss of functional 
class I major histocompatability complex (MHC) molecules and 
depleted CD8 T cells (Sankar et al., 2012), show no differences 
in time spent in the open arm of the EPM; however, they show 
increased risk assessment behaviors (Sankar et al., 2012). Mice 
lacking T cell receptor β and δ chains (TCRβ-/-δ-/-) and deficient 
of T cells showed reduced anxiety-like behavior in the EPM, 
light/dark test, and OF, whereas these behavioral differences 
are not observed in B cell deficient mice (Rilett et al., 2015). In 
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Table 1. Behavioral outcomes in germ-free mice
Behavioral Test
Sex/Strain/ 
Species Outcome Ref
GF, Conventionalized 
(8 w) GF mice
EPM F SW mice •	 GF	mice	spent	more	time	in	open	arms,	showed	
increased # of open arm entries, no activity difference
•	 Conventionalization	of	GF	mice	at	8	w	of	age	did	not	
reverse the behavioral phenotype
(Neufeld et al., 
2011a, 2011b)
GF, SPF
Conventionalized 
(dams prior to 
mating)
EPM
Light/Dark Test
OF
M NMRI •	 GF	mice	spent	more	time	in	open	arms	of	EPM	and	more	
time in light chamber of L/D test
•	 GF	mice	showed	increase	motor	activity	and	rearing	in	
OF
•	 Offspring	of	conventionalized	dams	spent	more	time	
in light chamber comparable to GF mice, however other 
behaviors normalized
(Heijtz et al., 2011)
GF, SPF
GF SW colonized with 
Balb/C or SW SPF 
microbiota
GF Balb/C colonized 
with Balb/C or SW 
SPF microbiota
Light/Dark Test; 
step-down
M Balb/C and 
SW mice
•	 SPF	Balb/C	mice	exposed	to	7 days	of	antibiotic	cocktail	
spent more time in the light chamber of the light/dark 
test and showed increased transitions; in addition, the 
stepped down faster from elevated platform
•	 Two	week	washout	following	antibiotic	treatment	
reversed the Behavioral effects and altered microbiota 
profile
•	 Antibiotic	treatment	of	GF	mice	did	not	alter	behavior
•	 Vagotomy	did	not	alter	antibiotic	effects	on	behavior
•	 GF	SW	mice	colonized	with	SPF	Balb/C	microbiota	
showed reduced exploratory behavior than GF SW mice 
colonized with SPF Swiss Webster microbiota
•	 GF	Balb/C	mice	colonized	with	SPF	SW	microbiota	
showed more exploratory behavior than GF Balb/C mice 
colonized with SPF Balb/C microbiota
(Bercik et al., 
2011a)
GF, Conventional, 
Conventionalized 
(P21) GF mice (GFC)
Light/Dark Test M and F SW 
mice
•	 GF	mice	transitioned	more	between	the	light	and	dark	
chamber in the light/dark test
•	 Conventionalization	of	GF	mice	at	P21	normalized	
behavior in the light/dark test
(Clarke et al., 2013)
GF
Conventionalized 
(P21) GF mice (GFC)
3 chamber social 
behavior; social 
transmission of 
food preference
M and F SW 
mice
•	 GF	mice	show	reduced	sociability	which	normalized	in	
GFC mice
•	 GF	mice	did	not	show	normal	social	preference	of	novel	
mouse which did not normalize in GFC mice
•	 GF	mice	showed	reduced	social	investigation	and	
increase self-grooming during the social transmission of 
food preference test
(Desbonnet  
et al., 2013)
Expt 1 – GF, GF 24 h in 
SPF conditions
Expt 2 – GF, EX- 
GF (offspring of 
conventionalized 
GF mice), Bi – GF 
monoassociated 
with Bifido 
infantis, Bc – GF 
monoassoicated 
with Clostridium 
coccoides
OF; marble  
burying test
M Balb/C  
mice
•	 Expt	1	-	GF	mice	retested	after	24h	exposure	to	normal	
housing conditions showed reduced number of marbles 
buried and reduced time spent in the periphery of 
the OF; no differences seen in GF mice retested in GF 
conditions
•	 Expt	2 –	reduced	number	of	marbles	buried	at	10	and	16	
w of age and reduced time spent in the periphery of the 
OF in EX-GF mice compared to GF mice at 7, 10 and 16 w 
of age, also reduced distance travelled in OF across time 
points
•	 Expt	2 –	Bc	mice	showed	reduced	time	spent	in	the	
periphery of the OF at 7 and 10 w of age and reduced 
number of marbles buried across time points
•	 Expt	2	-	Bi	mice	showed	reduced	activity	(distance	
travelled) in the OF across time points
(Nishino  
et al., 2013)
GF, SPF Social  
interaction; OF
M F344 stress- 
sensitive rats
•	 GF	rats	showed	less	sniffing	behavior	during	the	first	
2 min of the social interaction test
•	 GF	rats	showed	reduced	center	entries,	increased	latency	
to first move, and increased time spent in the corners of 
the open field (6 min test)
(Crumeyrolle- 
Arias et al., 
2014)
EPM, Elevated Plus Maze; EX-GF, the offspring of conventionalized GF Balb/C mice; F, female; GF, germ-free; M, male; OF, open field; SPF, specific pathogen free; SW, 
Swiss Webster
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the study with β2M−/−TAP−/− mice we observed a loss of sexual 
dimorphism in activity, exploratory, and anxiety-like behaviors 
compared to B6 mice (Sankar et al., 2012). This was also observed 
in TCRβ-/- δ-/- mice (Rilett et al., 2015). Considering the evidence 
of sexual dimorphisms in immune functioning (Weinstein et al., 
1984; Da Silva, 1999; De Leon-Nava et al., 2009), it is seems rea-
sonable and necessary to further examine a role for immune 
phenotype in sex differences in behavior.
Microbiota Produce Neurochemicals that 
Affect the Brain
In many of the studies that have addressed mechanisms by 
which microbes can influence behavior, the conclusions are that 
such mechanisms involve the immune system to some degree, 
as noted in the above section. This is not surprising given that 
such studies often involve the administration of a microorgan-
ism in a manner that nearly guarantees an immune system 
response. However, mechanisms by which microbiota-gut-brain 
communication can occur that are non-immune mediated are 
becoming an area of growing research interest (Lyte and Cryan, 
2014a).
The ability of bacteria to produce and recognize neurochem-
icals (Lyte, 2013) provides a mechanistic basis with which to 
examine the ability of the microbiota to influence the micro-
biome-gut-brain axis. The recognition that prokaryotic, as well 
as eukaryotic, microorganisms produce, as well as possess, 
receptors for a wide range of neuroendocrine hormones has in 
fact been known for decades (for reviews see Lenard, 1992, and 
Roshchina, 2010). The range of neurohormones that are found in 
microorganisms is extremely diverse, ranging from somatosta-
tin to acetylcholine to progesterone. Critically, microorganisms 
which inhabit the gastrointestinal tract are capable of producing 
neurochemicals that can bind to host receptors (intra- and extra-
intestinal) in sufficient quantities to effect neurophysiological 
changes in the host. Asano et  al. (2012) established that the 
microbiota is capable of the in situ production of the biologically 
active neuroendocrine hormones dopamine and norepineph-
rine, in quantities large enough to affect host neurophysiology.
Production and recognition of neurochemicals that are more 
commonly associated with mammals by prokaryotic and eukar-
yotic microorganisms has led to a new understanding of an evo-
lutionary-based mechanism by which microbes can influence 
host behavior and vice versa: namely, microbial endocrinology 
(Lyte, 2014a, 2014b; Lyte and Cryan, 2014b). Microbial endocri-
nology represents the intersection of the fields of microbiology 
and neurophysiology and had its beginnings in the demonstra-
tion that neurochemicals produced by the host during periods 
of stress, such as the biogenic amine norepinephrine, could dra-
matically increase the growth of bacteria both in vitro and in vivo 
(for review see Lyte, 2010).
Given that bacteria are prolific producers of neuroendocrine 
hormones, as well as other neuroactive compounds (Holzer and 
Farzi, 2014), it would seem reasonable to conclude that such 
bacterial production of neuroactive compounds within the gut 
lumen could influence either host-specific neural receptors 
within the gut or extra-intestinal neuronal sites following lumi-
nal uptake into the portal circulation. There are a number of 
reports that provide support that neurochemical production by 
bacteria within the gut can influence behavior in both human 
and animal model systems (Bravo et al., 2011; Messaoudi et al., 
2011a; Collins et al., 2013). Most often, these reports employ pro-
biotic bacteria, such as Lactobacillus or Bifidobacterium: many of 
the species belonging to these two genera are prolific producers 
of neurochemicals for which well-defined neural mechanisms 
are known and by which behavior may be modulated. Of par-
ticular interest, Bravo and colleagues (2011) observed reduced 
anxiety-like and depressive-like behavior in mice fed the pro-
biotic strain L.  rhamnosus (JB-1). Following probiotic adminis-
tration, they were able to demonstrate changes in the levels of 
GABAAα2 mRNA in those brain regions associated with the spe-
cific behavior (Bravo et al., 2011). Although they did not quantify 
the amount of GABA produced by the administered L. rhamnosus 
(JB-1) strain, the demonstration of a mechanism such as that 
mediated via central GABA receptor expression provides evi-
dence that the ability of bacteria to influence behavior can occur 
through a neurochemical-mediated route.
And as to whether bacteria are capable of producing enough 
quantities of neurochemicals to affect behavior, a recent study 
that employed the GABA-producing Lactobacillus brevis FPA 3709 
amply demonstrates that ability. In this functional food study, 
L.  brevis was used to enrich black soybean milk with GABA, 
which was then fed to rats subjected to the FST (Ko et al., 2013). 
The FST, in which animals are placed in a water-containing 
glass cylinder and the duration of immobility before the ani-
mals begin to swim is measured, is a well-recognized test of 
depressive-like behavior. In this study, the GABA-enriched soy-
bean milk significantly reduced the immobility time before 
the rats began to swim and was as effective as the selective 
serotonin reuptake inhibitor fluoxetine as an antidepressant 
(Ko et  al., 2013). The use and design of probiotics based on a 
microbial endocrinology-based approach has also been pro-
posed (Lyte, 2011).
Microbiota and Brain Imaging
Although much of the progress in understanding how the 
microbiota-gut-brain axis influences brain function and behav-
ior has been in preclinical studies, work is now moving forward 
in human populations. Alterations in the microbiota-gut-brain 
axis have been implicated in brain-gut disorders such as func-
tional gastrointestinal (GI) disorders (Mayer and Tillisch, 2011), 
inflammatory bowel diseases (Mayer et  al., 2014), obesity, and 
metabolic syndrome (Yau et  al., 2012). In addition, microbiota 
are also implicated in non-GI brain disorders, including anxi-
ety and depression, multiple sclerosis, Alzheimer’s disease, 
Parkinson’s disease, and autism (Cryan and Dinan, 2012; Foster 
and McVey Neufeld, 2013; Naseribafrouei et al., 2014; Jiang et al., 
2015; Mayer et al., 2015; Scheperjans et al., 2015). Results to date 
point to changes in microbiota composition and diversity in 
patient populations compared to healthy individuals: however, 
few studies have made direct links between gut microbiota and 
brain function. One approach to study gut-brain interactions 
in human populations is to combine manipulations of the gut 
microbiota with brain imaging and measures of symptoms of 
emotion (Tillisch et al., 2013). A recent report showed that probi-
otic ingestion affected brain functions in healthy women (Tillisch 
et  al., 2013). In a double blind, randomized, controlled study, 
individuals received that test product—a commercially available 
fermented milk product that contained B. animalis subsp lactis (B. 
Lactis), Lactoccouc lactis subsp lactis, L. delbrueckii subsp bulgaricus, 
and Streptococcus thermophiles—a non-fermented dairy product, 
or no treatment (Tillisch et al., 2013). This probiotic combination 
was previously shown to have no impact on the composition of 
the gut microbiota, but did modulate some metabolic pathways 
involved in polysaccharide degradation, including amino acid 
metabolism (McNulty et al., 2011). Interestingly, consumption of 
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the test product containing probiotics for 4 weeks was associ-
ated with reduced engagement of an extensive brain network 
in response to an emotion recognition task (Tillisch et al., 2013). 
The widely distributed brain network was increased in the no 
treatment group, not different in the individual who consumed 
the control product, and decreased in those who consumed the 
probiotic mixture (Tillisch et al., 2013). Ongoing work in the field 
of brain imaging includes an approach to connect gut microbial 
ecology (Saulnier et  al., 2011) with large-scale brain networks 
(Irimia and Van Horn, 2013). Such approaches will aid in our abil-
ity to determine how the microbiome influences brain function 
and to potentially identify multiple mediators of the gut-brain 
axis.
Experimental Challenges Ahead
The past 5 years have seen an amazing increase in our knowl-
edge of how bacteria signal to the brain and the implications 
this has for psychiatry. There are still many open questions, 
however. Firstly, the mechanisms of how the microbiota sig-
nals to the brain are only slowly being unraveled. The studies 
that have been performed to date have not yet conclusively 
demonstrated that a microbial endocrinology-based mecha-
nism can account for the observed ability of the gut micro-
biota to influence behavior. We are at the very early stages 
of research, which will need to employ experimental rigor 
that must be employed to unequivocally demonstrate that it 
is the actual production of a neurochemical in vivo by a spe-
cific microorganism, and not a non-neurochemical aspect of 
the microorganism, such as a cell wall component interacting 
with immune cells in the gut, that is responsible for a specific 
change in behavior. Further, receptor-specific binding within 
the gut or extra-intestinal site must be demonstrated for 
the specific neurochemical produced by the microorganism. 
Recently, a step-by-step experimental approach was intro-
duced to guide the experimental design for probiotics that 
seek to examine such microbial endocrinology–based mecha-
nisms (Lyte, 2011). Such experiments are currently under-
way in a number of laboratories, and will provide a definitive 
answer.
Secondly, the individual components of bacteria that are 
mediating their effects need to be disentangled. As the field 
continues to consider composition and diversity of the micro-
biota in natural, clinical, and experimental settings, the evolv-
ing field of metabolomics is advancing and assisting in our 
ability to better understand the signaling cascades and roles 
of bacterial products.
Thirdly, as most of the studies to date have been in rodents, 
further human studies are needed to determine if bacteria-
based interventions can indeed have a positive effect on men-
tal health, a so-called psychobiotic effect (Dinan et  al., 2013). 
Although some preliminary studies have focused on the altered 
composition of the microbiota in depression and autism, the 
time is now ripe for a comprehensive analysis of the microbiota 
in other disorders, including schizophrenia, anxiety, drug addic-
tion, and eating disorders (Bach-Mizrachi et  al., 2006; Dinan 
et al., 2014; Leclercq et al., 2014; Burokas et al., 2015; Fond et al., 
2015; Nemani et al., 2015), followed by mechanistic studies that 
will determine if such changes have any causal relationship to 
psychiatric symptomatology.
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